- SAB Biotherapeutics ( NASDAQ: SABS ) has received an additional $8.2M from the U.S. Department of Defense related to the closeout of the discontinued COVID-19 prototype research and development contract.
- This brings the total final closeout settlement to $16.8M received since November 2022.
- “Our work with the DoD has clinically validated our unique approach and accelerated SAB’s novel polyclonal antibody platform to Phase 3 stage of development,” said Eddie Sullivan, co-founder, President, and CEO of SAB Biotherapeutics.
- Based on its current operating plans and recent developments, SAB now expects cash and equivalents, and anticipated cash flows will be sufficient to fund its operating expenses and capex requirements through 2023.
For further details see:
SAB Biotherapeutics gets additional $8.2M in funding in closeout DoD contract